Patent ID: 6960595
Filing Date: 2005-11-01
Classification: C07D

Abstract:
1. A compound of formula I: or a stereoisomer or pharmaceutically acceptable salt thereof, wherein; ring M is substituted with 0-1 R ring P, including P one of P G is a group of formula IIa or IIb: ring D, including the two atoms of Ring E to which it is attached, is a 5-6 membered non-aromatic ring consisting of carbon atoms, 0-1 double bonds, and 0-2 heteroatoms selected from the group consisting of N, O, and S(O) alternatively, ring D, including the two atoms of Ring E to which it is attached, is a 5-6 membered aromatic system consisting of carbon atoms and 0-2 heteroatoms selected from the group consisting of N, O, and S(O) E is selected from phenyl, pyridyl, pyrimidyl, pyrazinyl, and pyridazinyl, and is substituted with 1-2 R; alternatively, the bridging portion of ring D is absent, and ring E is selected from phenyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, pyrrolyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, triazolyl, thienyl, and thiazolyl, and ring E is substituted with 1-2 R; R is selected from H, C alternatively, when 2 R groups are attached to adjacent atoms, they combine to form methylenedioxy or ethylenedioxy; A is selected from: B is selected from phenyl, pyrrolidino, N-pyrrolidino-carbonyl morpholino, N-morpholino-carbonyl, 1,2,3-triazolyl, imidazolyl, and benzimidazolyl, and is substituted with 0-1 R G Z is selected from a bond, —(CR R R R R R R R R alternatively, R R R R R R R alternatively, one R R alternatively, one R R R R R R alternatively, R R n, at each occurrence, is selected from 0, 1, 2, and 3; p, at each occurrence, is selected from 0, 1, and 2; r, at each occurrence, is selected from 0, 1, 2, 3, 4, 5, and 6; t, at each occurrence, is selected from 0, 1, 2, and 3; provided that: